This data analysis examines the fulfillment of postmarketing requirements associated with drugs granted accelerated approval for oncology indications in the past 6 years.
No takes yet. Share an insight, caveat, or question.
Zettler et al. (2018) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: